Evidence map›Paper›PMID 37540679›Full record

ArticlePloS one2023

Analysis of altered level of blood-based biomarkers in prognosis of COVID-19 patients.

Mahendra Raj Shrestha, Ajaya Basnet, Basanta Tamang, Sudip Khadka, Rajendra Maharjan, Rupak Maharjan, Arun Bahadur Chand, Suresh Thapa, Shiba Kumar Rai

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. SpOBiomedicines · 2025
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Mahendra Raj ShresthaDepartment of Clinical Laboratory, Nepal Armed Police Force Hospital, Kathmandu, Bagmati, Nepal.ORCID 0000-0002-8292-5757
Ajaya BasnetDepartment of Medical Microbiology, Shi-Gan International College of Science and Technology, Tribhuvan University, Kathmandu, Bagmati, Nepal.ORCID 0000-0003-4991-6389
Basanta TamangDepartment of Clinical Laboratory, Nepal Armed Police Force Hospital, Kathmandu, Bagmati, Nepal.
Sudip KhadkaDepartment of Microbiology and Immunology, Stanford University, Palo Alto, California, United States of America.
Rajendra MaharjanDepartment of Clinical Laboratory, Nepal Armed Police Force Hospital, Kathmandu, Bagmati, Nepal.
Rupak MaharjanDepartment of Clinical Laboratory, Nepal Armed Police Force Hospital, Kathmandu, Bagmati, Nepal.
Arun Bahadur ChandDepartment of Clinical Laboratory, KIST Medical College and Teaching Hospital, Lalitpur, Bagmati, Nepal.
Suresh ThapaDepartment of Clinical Laboratory, Nepal Armed Police Force Hospital, Kathmandu, Bagmati, Nepal.
Shiba Kumar RaiResearch Department, Nepal Medical College Teaching Hospital, Kathmandu, Bagmati, Nepal.
KIST Medical College · NPNepal Medical College Teaching Hospital · NPStanford University · USTribhuvan University · NP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionImmune and inflammatory responses developed by the patients with Coronavirus Disease 2019 (COVID-19) during rapid disease progression result in an altered level of biomarkers. Therefore, this study aimed to analyze levels of blood-based biomarkers that are significantly altered in patients with COVID-19.

methodsA cross-sectional study was conducted among COVID-19 diagnosed patients admitted to the tertiary care hospital. Several biomarkers-biochemical, hematological, inflammatory, cardiac, and coagulatory-were analyzed and subsequently tested for statistical significance at P<0.01 by using SPSS version 17.0.

resultsA total of 1,780 samples were analyzed from 1,232 COVID-19 patients (median age 45 years [IQR 33-57]; 788 [63.96%] male). The COVID-19 patients had significantly (99% Confidence Interval, P<0.01) elevated levels of glucose, urea, alanine transaminase (ALT), aspartate aminotransaminase (AST), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), white blood cell (WBC), C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6), ferritin, D-Dimer, and creatinine phosphokinase-MB (CPK-MB) compared to the control group. However, the levels of total protein, albumin, and platelets were significantly (P<0.01) lowered in COVID-19 patients compared to the control group. The elevated levels of glucose, urea, WBC, CRP, D-Dimer, and LDH were significantly (P<0.01) associated with in-hospital mortality in COVID-19 patients.

conclusionsAssessing and monitoring the elevated levels of glucose, urea, ALT, AST, ALP, WBC, CRP, PCT, IL-6, ferritin, LDH, D-Dimer, and CPK-MB and the lowered levels of total protein, albumin, and platelet could provide a basis for evaluation of improved prognosis and effective treatment in patients with COVID-19.

Indexed as

COVID-19BiomarkersC-Reactive ProteinCross-Sectional StudiesFemaleFerritinsGlucoseHumansInterleukin-6MaleMiddle AgedPrognosisRetrospective StudiesSARS-CoV-2BiomarkersC-Reactive ProteinFerritinsGlucoseInterleukin-6

Identifiers

PMID37540679
PMCPMC10403103
OpenAlexW4385568234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.